<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001513'>Obesity</z:hpo> is a major risk factor for the development of <z:mp ids='MP_0002055'>diabetes</z:mp> and predisposes individuals to <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Together these pathologies increase the risk for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>), the major cause of morbidity and mortality in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) </plain></SENT>
<SENT sid="2" pm="."><plain>Worsening trends in <z:hpo ids='HP_0001513'>obesity</z:hpo> and T2DM raise a serious conundrum, namely, how to control blood <z:chebi fb="105" ids="17234">glucose</z:chebi>, blood pressure, and <z:chebi fb="23" ids="18059">lipids</z:chebi> when many <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents cause <z:mp ids='MP_0005456'>weight gain</z:mp> and thereby exacerbate other <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> associated with T2DM </plain></SENT>
<SENT sid="3" pm="."><plain>Further, evidence suggests that some established <z:chebi fb="0" ids="35674">antihypertensive agents</z:chebi> may worsen <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Many patients who are <z:mp ids='MP_0001261'>obese</z:mp>, hypertensive, and/or hyperlipidaemic fail to achieve blood pressure, <z:chebi fb="23" ids="18059">lipid</z:chebi> and glycaemic goals, and this failure may in part be explained by physician reluctance to utilize complex combination regimens for fear of off-target effects </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, a clear need exists for clinicians to understand the risks and benefits of different pharmacologic, and indeed non-pharmacologic, options in order to maximize treatment outcomes </plain></SENT>
<SENT sid="6" pm="."><plain>While intensive lifestyle modification remains an elusive gold standard, newer <z:mp ids='MP_0002055'>diabetes</z:mp> targets, including the incretin axis, may offer greater cardiovascular risk reduction than other antidiabetes therapies, although definitive clinical trial data are needed </plain></SENT>
<SENT sid="7" pm="."><plain>The glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1) receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> exenatide and liraglutide and the dipeptidyl peptidase-4 (DPP-4) inhibitors <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> and vildagliptin effectively lower HbA1c; exenatide and liraglutide reduce weight and blood pressure and improve <z:chebi fb="23" ids="18059">lipid</z:chebi> profiles </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="40237">Sitagliptin</z:chebi> and vildagliptin are weight neutral but also appear to improve <z:chebi fb="23" ids="18059">lipid</z:chebi> profiles </plain></SENT>
<SENT sid="9" pm="."><plain>Integration of incretin therapies into the therapeutic armamentarium is a promising approach to improving outcomes in T2DM, and perhaps even in reducing complications of T2DM, such as co-morbid <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Additional long-term studies, including <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> end-point studies, will be necessary to determine the appropriate places for incretin-based therapies in treatment algorithms </plain></SENT>
</text></document>